Catalyst Pharmaceuticals CPRX reported adjusted earnings of 68 cents per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of 42 cents. The company had recorded adjusted ...

In recent months, Catalyst Pharmaceuticals secured U.S. patent protections extending Firdapse’s exclusivity to 2035, resolved key patent disputes, expanded Firdapse’s label to pediatric LEMS patients, ...

CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

What Tools Were Used in the Studies for Lambert-Eaton Myasthenic Syndrome (LEMS)? Before describing how Firdapse was studied, it is important to understand the tools that were used in the studies.

Catalyst Pharmaceuticals, Inc. CPRX announced positive top-line results from a second phase III study of Firdapse. As the lead pipeline candidate of the company, Firdapse is being developed for the ...

(RTTNews) - Catalyst Pharmaceuticals, Inc. (CPRX), a commercial-stage biopharmaceutical company, Tuesday announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE or amifampridine Tablets 10 ...

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and ...

Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...

We issued an updated research report on Catalyst Pharmaceuticals Inc. CPRX on Sep 7, 2020. Catalyst’s share price has declined 17.9% compared with the industry’s decline of 9% in the year so far. The ...

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation ...